| Literature DB >> 25739764 |
Stephen M Hatfield1, Jorgen Kjaergaard1, Dmitriy Lukashev1, Taylor H Schreiber2, Bryan Belikoff1, Robert Abbott1, Shalini Sethumadhavan1, Phaethon Philbrook1, Kami Ko1, Ryan Cannici1, Molly Thayer1, Scott Rodig3, Jeffrey L Kutok3, Edwin K Jackson4, Barry Karger5, Eckhard R Podack2, Akio Ohta1, Michail V Sitkovsky6.
Abstract
Antitumor T cells either avoid or are inhibited in hypoxic and extracellular adenosine-rich tumor microenvironments (TMEs) by A2A adenosine receptors. This may limit further advances in cancer immunotherapy. There is a need for readily available and safe treatments that weaken the hypoxia-A2-adenosinergic immunosuppression in the TME. Recently, we reported that respiratory hyperoxia decreases intratumoral hypoxia and concentrations of extracellular adenosine. We show that it also reverses the hypoxia-adenosinergic immunosuppression in the TME. This, in turn, stimulates (i) enhanced intratumoral infiltration and reduced inhibition of endogenously developed or adoptively transfered tumor-reactive CD8 T cells, (ii) increased proinflammatory cytokines and decreased immunosuppressive molecules, such as transforming growth factor-β (TGF-β), (iii) weakened immunosuppression by regulatory T cells, and (iv) improved lung tumor regression and long-term survival in mice. Respiratory hyperoxia also promoted the regression of spontaneous metastasis from orthotopically grown breast tumors. These effects are entirely T cell- and natural killer cell-dependent, thereby justifying the testing of supplemental oxygen as an immunological coadjuvant to combine with existing immunotherapies for cancer.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25739764 PMCID: PMC4641038 DOI: 10.1126/scitranslmed.aaa1260
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956